Faculty

Back to Index
Diane Marie Da Silva, PhD, MS
Assistant Professor of Research Obstetrics & Gynecology
Obstetrics & Gynecology
NRT 7517 Health Sciences Campus Los Angeles
+1 323 442 3868

Overview

Dr. Da Silva's current research interests span multiple areas of study that include applying immune modulation strategies to enhance natural and vaccine-induced immunity against Human papillomavirus, investigating the molecular and cellular determinants in the tumor microenvironment that lead to cervical and ovarian cancer progression and metastasis, and assessing the clinical significance of the cervico-vaginal microbiota in relation to chronic inflammation and cervical precancerous lesion progression.

Dr. Da Silva has spent the past 15 years studying human papillomavirus (HPV) interactions with host immune cell receptors and immune escape mechanisms used by HPV, and has been involved with development of therapeutic vaccine strategies against HPV-induced cancers. She has broad expertise and skills associated with immunology, oncology and infectious disease research, immunotherapeutics, vaccine immunogenicity and efficacy, pre-clinical vaccine/adjuvant development, small animal syngeneic and xenograft tumor models, clinical translational research, and analysis of immune responses and biomarkers in human samples.

Dr. Da Silva is the course director for a newly developed undergraduate Introductory course in Modern Oncology and Cancer Biology for the USC Minor in Health Care Studies that started in Spring 2015.

Publications

Woodham AW, Yan L, Skeate JG, van der Veen D, Brand HH, Wong MK, Da Silva DM, Kast WM. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation. Papillomavirus Res. 2016 Dec; 2:21-30. View in: PubMed

Woodham AW, Sanna AM, Taylor JR, Skeate JG, Da Silva DM, Dekker LV, Kast WM. Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro. Virol J. 2016 Nov 18; 13(1):187. View in: PubMed

Nicol AF, Brunette LL, Nuovo GJ, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Coutinho JR, Vianna de Andrade C, Oliveira NS, Woodham AW, Da Silva DM, Kast WM. Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. J Acquir Immune Defic Syndr. 2016 Sep 1; 73(1):27-33. View in: PubMed

Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 Jul; 30(7):291-306. View in: PubMed

Skeate JG, Woodham AW, Einstein MH, Da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016 Jun 2; 12(6):1418-29. View in: PubMed

Da Silva DM, Woodham AW, Naylor PH, Egan JE, Berinstein NL, Kast WM. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. J Interferon Cytokine Res. 2016 May; 36(5):291-301. View in: PubMed

Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, Brand HE, Wong MK, McKee GM, Salazar AM, Kast WM. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015 Dec 1; 1:12-21. View in: PubMed

Skeate JG, Porras TB, Woodham AW, Jang JK, Taylor JR, Brand HE, Kelly TJ, Jung JU, Da Silva DM, Yuan W, Kast WM. Herpes Simplex Virus downregulation of secretory leukocyte protease inhibitor enhances Human Papillomavirus type 16 infection. J Gen Virol. 2015 Nov 10. View in: PubMed

Da Silva DM, Woodham AW, Skeate JG, Rijkee LK, Taylor JR, Brand HE, Muderspach LI, Roman LD, Yessaian AA, Pham HQ, Matsuo K, Lin YG, McKee GM, Salazar AM, Martin Kast W. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized poly-I:C. Clin Immunol. 2015 Sep 7. View in: PubMed

Bogaert L, Woodham AW, Da Silva DM, Martens A, Meyer E, Kast WM. A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours. J Gen Virol. 2015 Sep; 96(9):2764-8. View in: PubMed

Woodham AW, Taylor JR, Jimenez AI, Skeate JG, Schmidt T, Brand HE, Da Silva DM, Kast WM. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection. J Antimicrob Chemother. 2015 Jun; 70(6):1686-90. View in: PubMed

Yan L, Silva DM, Verma B, Gray A, Brand HE, Skeate JG, Porras TB, Kanodia S, Kast WM. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes. Prostate. 2015 Feb; 75(3):280-91. View in: PubMed

Yan L, Woodham AW, Da Silva DM, Kast WM. Functional Analysis of HPV-Like Particle-Activated Langerhans Cells In Vitro. Methods Mol Biol. 2015; 1249:333-50. View in: PubMed

Woodham AW, Raff AB, Da Silva DM, Kast WM. Molecular analysis of human papillomavirus virus-like particle activated langerhans cells in vitro. Methods Mol Biol. 2015; 1249:135-49. View in: PubMed

Woodham AW, Raff AB, Raff LM, Da Silva DM, Yan L, Skeate JG, Wong MK, Lin YG, Kast WM. Inhibition of langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression. J Immunol. 2014 May 15; 192(10):4748-57. View in: PubMed

Da Silva DM, Movius CA, Raff AB, Brand HE, Skeate JG, Wong MK, Kast WM. Suppression of Langerhans cell activation is conserved amongst human papillomavirus a and ß genotypes, but not a µ genotype. Virology. 2014 Mar; 452-453:279-86. View in: PubMed

Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM. The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol. 2013 Jun; 87(11):6062-72. View in: PubMed

Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection. PLoS One. 2012; 7(8):e43519. View in: PubMed

Kanodia S, Da Silva DM, Karamanukyan T, Bogaert L, Fu YX, Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res. 2010 May 15; 70(10):3955-64. View in: PubMed

Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan 15; 116(2):424-31. View in: PubMed

Fahey LM, Raff AB, Da Silva DM, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J Immunol. 2009 Nov 15; 183(10):6151-6. View in: PubMed

Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, Joea DK, Lantzy L, Carrillo MA, Gross TM, Malyankar UM, Chiang CS, Da Silva DM, Kündig TM, Kast WM, Qiu Z, Bot A. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009 Oct 1; 15(19):6167-76. View in: PubMed

Fahey LM, Raff AB, Da Silva DM, Kast WM. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009 Mar 1; 182(5):2919-28. View in: PubMed

Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008 Jan 15; 122(2):247-59. View in: PubMed

Chiriva-Internati M, Cobos E, Da Silva DM, Kast WM. Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun. 2008; 8:8. View in: PubMed

Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J Immunol. 2007 Jun 15; 178(12):7587-97. View in: PubMed

Warrino DE, Olson WC, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Da Silva DM, Kast WM, Storkus WJ. Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. Hum Immunol. 2005 Jul; 66(7):762-72. View in: PubMed

Fausch SC, Fahey LM, Da Silva DM, Kast WM. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol. 2005 Jun 1; 174(11):7172-8. View in: PubMed

Fausch SC, Da Silva DM, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine. 2005 Feb 25; 23(14):1720-9. View in: PubMed

Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine. 2003 Jul 4; 21(23):3219-27. View in: PubMed

Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 2003 Jul 1; 63(13):3478-82. View in: PubMed

Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. HPV protein/peptide vaccines: from animal models to clinical trials. Front Biosci. 2003 Jan 1; 8:s81-91. View in: PubMed

Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol. 2003; 16(2):111-21. View in: PubMed

Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol. 2002 Sep 15; 169(6):3242-9. View in: PubMed

Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology. 2002; 45(4-6):300-7. View in: PubMed

Powered bySC CTSI